Adaptive Biotechnologies Corp Stock Performance

ADPT Stock  USD 16.04  0.50  3.22%   
On a scale of 0 to 100, Adaptive Biotechnologies holds a performance score of 6. The firm shows a Beta (market volatility) of 0.0753, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Adaptive Biotechnologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Adaptive Biotechnologies is expected to be smaller as well. Please check Adaptive Biotechnologies' coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Adaptive Biotechnologies' price patterns will revert.

Risk-Adjusted Performance

Mild

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Adaptive Biotechnologies Corp are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Adaptive Biotechnologies unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
3.22
Five Day Return
(9.99)
Year To Date Return
0.82
Ten Year Return
(60.20)
All Time Return
(60.20)
1
Disposition of 133032 shares by Sharon Benzeno of Adaptive Biotechnologies at 8.46 subject to Rule 16b-3
11/20/2025
2
Adaptive Biotechnologies Is Up 15.4 percent After Raising Guidance on Strong MRD Test Momentum Has the Bull Case Changed
11/21/2025
3
Disposition of 124998 shares by Robins Chad M of Adaptive Biotechnologies at 18.94 subject to Rule 16b-3
12/01/2025
4
Adaptive Biotechnologies Valuation Check After ASH clonoSEQ Data Spotlight and Q3 Earnings Beat
12/08/2025
5
Disposition of 19423 shares by Francis Lo of Adaptive Biotechnologies at 8.46 subject to Rule 16b-3
12/17/2025
6
Disposition of 2194 shares by Francis Lo of Adaptive Biotechnologies at 8.46 subject to Rule 16b-3
12/22/2025
7
Acquisition by Francis Lo of 1100 shares of Adaptive Biotechnologies at 3.99 subject to Rule 16b-3
12/29/2025
8
Disposition of 3125 shares by Francis Lo of Adaptive Biotechnologies at 3.99 subject to Rule 16b-3
01/02/2026
9
Disposition of 124998 shares by Robins Chad M of Adaptive Biotechnologies at 15.59 subject to Rule 16b-3
01/05/2026
10
Disposition of 10000 shares by Harlan Robins of Adaptive Biotechnologies at 16.44 subject to Rule 16b-3
01/06/2026
11
Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026
01/13/2026
12
First Week of March 20th Options Trading For Adaptive Biotechnologies - Nasdaq
01/16/2026
13
Guggenheim Raises Price Target for ADPT to 21, Maintains Buy Rating ADPT Stock News - GuruFocus
01/26/2026
14
Disposition of 124998 shares by Robins Chad M of Adaptive Biotechnologies at 18.44 subject to Rule 16b-3
02/02/2026
15
Adaptive Biotechnologies Cut to Hold at Wall Street Zen
02/03/2026
16
Disposition of 2145 shares by Kyle Piskel of Adaptive Biotechnologies at 12.14 subject to Rule 16b-3
02/04/2026
17
Adaptive Biotechnologies Insider Harlan Robins Sells 34,668 Shares
02/05/2026
18
Adaptive Biotechnologies targets 30 clonoSEQ test volume growth in 2026 while expanding margins and data partnerships
02/06/2026
19
Disposition of 10000 shares by Harlan Robins of Adaptive Biotechnologies at 16.61 subject to Rule 16b-3
02/12/2026
Begin Period Cash Flow68 M
Total Cashflows From Investing Activities77.8 M

Adaptive Biotechnologies Relative Risk vs. Return Landscape

If you would invest  1,371  in Adaptive Biotechnologies Corp on November 16, 2025 and sell it today you would earn a total of  233.00  from holding Adaptive Biotechnologies Corp or generate 16.99% return on investment over 90 days. Adaptive Biotechnologies Corp is currently generating 0.3697% in daily expected returns and assumes 4.8093% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Adaptive, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Adaptive Biotechnologies is expected to generate 6.24 times more return on investment than the market. However, the company is 6.24 times more volatile than its market benchmark. It trades about 0.08 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of risk.

Adaptive Biotechnologies Target Price Odds to finish over Current Price

The tendency of Adaptive Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 16.04 90 days 16.04 
about 67.96
Based on a normal probability distribution, the odds of Adaptive Biotechnologies to move above the current price in 90 days from now is about 67.96 (This Adaptive Biotechnologies Corp probability density function shows the probability of Adaptive Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Adaptive Biotechnologies has a beta of 0.0753. This suggests as returns on the market go up, Adaptive Biotechnologies average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Adaptive Biotechnologies Corp will be expected to be much smaller as well. Additionally Adaptive Biotechnologies Corp has an alpha of 0.2217, implying that it can generate a 0.22 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Adaptive Biotechnologies Price Density   
       Price  

Predictive Modules for Adaptive Biotechnologies

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Adaptive Biotechnologies. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
11.4516.2621.07
Details
Intrinsic
Valuation
LowRealHigh
12.6017.4122.22
Details
8 Analysts
Consensus
LowTargetHigh
18.9820.8623.15
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.15-0.13-0.12
Details

Adaptive Biotechnologies Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Adaptive Biotechnologies is not an exception. The market had few large corrections towards the Adaptive Biotechnologies' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Adaptive Biotechnologies Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Adaptive Biotechnologies within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.22
β
Beta against Dow Jones0.08
σ
Overall volatility
1.65
Ir
Information ratio 0.04

Adaptive Biotechnologies Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Adaptive Biotechnologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Adaptive Biotechnologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Adaptive Biotechnologies had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 276.98 M. Net Loss for the year was (159.59 M) with profit before overhead, payroll, taxes, and interest of 111.85 M.
Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (95.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69.
Adaptive Biotechnologies has a poor financial position based on the latest SEC disclosures
Over 100.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Disposition of 10000 shares by Harlan Robins of Adaptive Biotechnologies at 16.61 subject to Rule 16b-3

Adaptive Biotechnologies Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Adaptive Stock often depends not only on the future outlook of the current and potential Adaptive Biotechnologies' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Adaptive Biotechnologies' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding151.7 M
Cash And Short Term Investments227 M

Adaptive Biotechnologies Fundamentals Growth

Adaptive Stock prices reflect investors' perceptions of the future prospects and financial health of Adaptive Biotechnologies, and Adaptive Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adaptive Stock performance.

About Adaptive Biotechnologies Performance

Assessing Adaptive Biotechnologies' fundamental ratios provides investors with valuable insights into Adaptive Biotechnologies' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Adaptive Biotechnologies is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 50.23  47.72 
Return On Tangible Assets(0.15)(0.16)
Return On Capital Employed(0.14)(0.14)
Return On Assets(0.12)(0.12)
Return On Equity(0.27)(0.29)

Things to note about Adaptive Biotechnologies performance evaluation

Checking the ongoing alerts about Adaptive Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adaptive Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Adaptive Biotechnologies had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 276.98 M. Net Loss for the year was (159.59 M) with profit before overhead, payroll, taxes, and interest of 111.85 M.
Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (95.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69.
Adaptive Biotechnologies has a poor financial position based on the latest SEC disclosures
Over 100.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Disposition of 10000 shares by Harlan Robins of Adaptive Biotechnologies at 16.61 subject to Rule 16b-3
Evaluating Adaptive Biotechnologies' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Adaptive Biotechnologies' stock performance include:
  • Analyzing Adaptive Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adaptive Biotechnologies' stock is overvalued or undervalued compared to its peers.
  • Examining Adaptive Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Adaptive Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adaptive Biotechnologies' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Adaptive Biotechnologies' stock. These opinions can provide insight into Adaptive Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Adaptive Biotechnologies' stock performance is not an exact science, and many factors can impact Adaptive Biotechnologies' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.